Universitätsklinikum Erlangen is the first in the world to use CAR T-cells to successfully treat a patient suffering from a severe case of muscle inflammation (myositis). The disease is triggered by a malfunction in the immune system that leads to inflammation of the muscles, and the risk of developing a very severe form of the disease is high. The Lancet has now published news of the successful treatment in a case report.
When the 41 year old Mr. S. noticed a dramatic deterioration in this health last year, he initially put it down to a viral infection. However, his health took a dramatic turn for the worse when he was suddenly no longer to move more than a few feet and was barely able to stand up. His symptoms were caused by a severe autoimmune disease affecting his muscles, joints, skin and lungs belonging to the group of anti-immune muscle inflammatory diseases (myositis). The diagnosis: anti-synthetase syndrome.
The name anti-synthetase syndrome is derived from the observation that the enzymes required for the synthesis of amino acids known as aminoacyl-tRNA synthetases are attacked in error by the immune system. This severely impacts the function of various cells.
Comments are closed.